ESR1 and breast cancer: Similarly, DNA and RNA sequencing and live cell imaging plus single-cell RNA-sequencing of metastatic ER+ breast cancer patients showed that pre-existing minor subclones become dominant after chemotherapy, indicating selection for resistance phenotypes [54,55], similarly to what was initially described for CML, lung cancer and melanoma [56].